United States: The USPTO Issues Guidelines For Subject Matter Eligibility In View Of The Supreme Court's Myriad And Prometheus Decisions

Last Updated: September 2 2014
Article by Miguel A. Lopez, Ph.D. and Stefan J. Kirchanski

The U.S. Supreme Court's decisions in Molecular Pathology v. Myriad Genetics, Inc. (Myriad) and Mayo Collaborative Services v. Prometheus Laboratories (Prometheus), and its subsequent interpretations of 35 U.S.C. §101, have sparked tremendous controversy in the biotech industry. Similarly, the USPTO's interpretation of the Supreme Court's rulings as represented in its Guidance has not been without controversy. In last month's issue of IP Buzz, we summarized and highlighted the key points of the guide. In this month's article, we will discuss the guide's potential implications for inventors and legal service providers.

As touched upon in last month's article, the USPTO's Guidance in view of Myriad and Prometheus has been received with mixed reviews from the biotech and legal professions. On one hand, professionals appreciate that the USPTO was placed in a difficult position and the prompt issuance of a Guidance to instruct examiners on claims comprising natural products and/or natural laws.  Proponents believe that the Guidance will be refined as the USPTO has made it clear that it is willing to accept feedback from the community.

However, proponents for the Guidance seem to be in the minority, with many biotech and legal professionals criticizing the USPTO's interpretation of the Supreme Court's rulings.  Critics contend that the Guidance in effect goes beyond what the Supreme Court actually ruled in the recent patent eligibility cases.  They point out that the Supreme Court limited the scope of its decisions and cautioned against over-interpretation, while the Guidance appears to be less measured and contrary to the Office's previous practices.

For instance, there are many previously issued patents pertaining to isolated enzymes, chemicals, naturally occurring antibiotics, and other "products of nature." However, based on the Guidance, it would appear that none of the following are patent-eligible subject matter: isolated chemical compound from crude oil useful as a lubricant, isolated chemical compound from plant useful as a drug, isolated antibiotic produced by bacteria, isolated protein from animal useful to cure/ameliorate human disease, and isolated plant/human genes/proteins (unless claimed as cDNA). In particular, the Guidance seems to call into question the longstanding Office policy of considering highly purified natural products as being patent eligible. In Myriad, the Supreme Court sidestepped this problem by indicating that their decision necessarily applied only to DNA and that DNA was unusual because DNA can be viewed as information as well as a chemical compound.

Regardless of one's views concerning the Guidance, inventors and patent practitioners must now try to adopt methods of ensuring meaningful patent protection for intellectual property that can be interpreted as containing a "product of nature" or as involving a "natural law." In the case of protecting intellectual property that might contain a "product of nature" (as understood by an examiner), one might consider including multiple claims having varying degrees of modifications to the naturally occurring product. At the same time, if one is to apply for a patent in Europe, it is important to keep in mind that European patent law thus far remains unchanged in view of Myriad. As such, although Europe forbids the patenting of particular human genes or elements, one can still claim such a gene or element so long as an industrial application for the gene or element is disclosed in the application. In summary, if claiming a product that might contain a "product of nature," it would be advisable to include broad claims that might be allowable in Europe (or other foreign patent offices) as well as subsequent claims with further modifications to the product.

Similarly, when protecting intellectual property involving a "law of nature," for U.S. filings, one must take care to: 1) limit the claim(s) to a particular application of the natural law, 2) not preempt all uses of the natural law, and 3) include unconventional steps that integrate the natural law into the claimed process which applies it. It is also advisable to keep one's claim(s) as broad as possible when filing in Europe (or other foreign patent offices), while still obeying the particular laws of the European Patent Office (EPO). For example, although in Prometheus the Supreme Court ruled that diagnostic patents based solely on the application of a natural law are no longer patentable in the U.S., the EPO holds that an invention involving the practical application of a discovery or theory is patentable (with certain limitations pertaining to interaction with and treatment of a human/animal body). As such, a claim to the diagnostic invention at the center of Prometheus was previously allowed by the EPO as an in vitro method for determining the efficacy of a treatment. Thus, it is important to determine if one's product can be interpreted to contain a "law of nature" and appropriately adjust one's claims for prosecution in the U.S. versus abroad.

Going forward, it will be interesting to see how the Guidance impacts the types of patents and claims applied for by inventors both inside and outside the biotechnology industry, as the concepts of "natural products" and "laws of nature" extend not just to chemicals and biological matter. Ultimately, the Guidance is simply an administrative tool that has no force of law. The implications of the Supreme Court's decisions and the impact of this Guidance will undoubtedly take many years to unfold and will inevitably be shaped by litigation and judicial decisions. For instance, it seems likely to the authors that should the USPTO deny patentability of natural products based on isolation and purity, the courts may not uphold such a denial. Similarly, court challenges to the validity of currently existing purified natural product patents are not likely to succeed, at least on Myriad grounds. There has not been sufficient time for any of possible approaches suggested above to demonstrate success (or failure) during prosecution of a patent application. These points are presented for discussion purposes and not as suggested actions.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
Pepper Hamilton LLP
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Pepper Hamilton LLP
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions